Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.69 |
| ▸ | LYN | P07948 | 1/20 | 0.69 |
| ▸ | BTK | Q06187 | 1/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 19/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 19/20 | 0.68 |
| ▸ | PIK3CB | P42338 | 19/20 | 0.68 |
| ▸ | PIK3CG | P48736 | 19/20 | 0.68 |
| ▸ | PRKDC | P78527 | 19/20 | 0.68 |
| ▸ | ABL1 | P00519 | 18/20 | 0.68 |
| ▸ | EGFR | P00533 | 18/20 | 0.68 |
| ▸ | HCK | P08631 | 18/20 | 0.68 |
| ▸ | SRC | P12931 | 18/20 | 0.68 |
| ▸ | KDR | P35968 | 18/20 | 0.68 |
| ▸ | MTOR | P42345 | 18/20 | 0.68 |
| ▸ | EPHB4 | P54760 | 18/20 | 0.68 |
| ▸ | PI4KB | Q9UBF8 | 9/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317659 | 0.97 | LCK (0.73) | LCKLYNBTKPIK3CDPIK3CA | |
| SCHEMBL23997156 | 0.96 | LCK (0.71) | LCKLYNBTKPIK3CDPIK3CA | |
| SCHEMBL23997146 | 0.95 | BTK (0.65) | LCKLYNBTKPIK3CDPIK3CA | |
| SCHEMBL13019691 | 0.90 | PIK3CD (0.72) | LCKLYNBTKPIK3CDPIK3CA | |
| SCHEMBL19335163 | 0.90 | BTK (0.77) | LCKLYNBTKPIK3CDPIK3CA | |
| SCHEMBL24096496 | 0.89 | PIK3CD (0.61) | LCKLYNBTKPIK3CDPIK3CA | |
| SCHEMBL23997158 | 0.89 | SRC (0.61) | LCKLYNBTKPIK3CDPIK3CA | |
| SCHEMBL20351824 | 0.88 | BTK (0.75) | LCKLYNBTKPIK3CDPIK3CA | |
| SCHEMBL15613465 | 0.87 | PIK3CD (0.72) | LCKLYNBTKPIK3CDPIK3CA | |
| SCHEMBL5804520 | 0.87 | PIK3CD (0.75) | LCKLYNBTKPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| CN-116075513-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-4161933-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2021252488-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252488-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021226547-A2 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226547-A2 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | LCK 1581/4885LYN 410/4885BTK 988/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | LCK 3727/4885LYN 1544/4885BTK 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.